Law360, New York (February 3, 2015, 6:12 PM EST) -- Hospira Inc. on Tuesday urged the Federal Circuit to reverse a decision upholding the validity of a patent for blockbuster infection drug Cubicin, saying the lower court should have invalidated Cubist Pharmaceuticals Inc.'s patent because a correction certificate drastically changed the chemical described.
Although a Delaware federal judge had invalidated four Cubicin patents, he ruled that Hospira had infringed a fifth patent, which Hospira said in its appellate brief was a mistake because the U.S. Patent and Trademark Office had issued an invalid certificate of correction and was an improper recapture.
"[A]ll agree that the change is anything but minor from...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!